Cancer Research UK (CRUK) has signed a collaboration agreement with Teon Therapeutics to advance early clinical development of the latter’s new cancer drug.
The focus of the agreement is Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist, TT-702.
Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702. This will be led by a team at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
The Centre for Drug Development, Teon and a team of clinical investigators led by professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021.
Read more: http://www.pharmatimes.com/news/cancer_research_uk_teams_up_with_teon_on_new_cancer_drug_1364446

http://www.pharmatimes.com/news/pfizers_tick-borne_encephalitis_vaccine_gets_us_priority_review_1364131

We have a fairly ambitious pitch (pharma communication agency). This mission relies 80% on a medical strategic writer (EN). Global mission of ± 300h spread over 2 to 3 months. Would anyone be able to take on this assignment?

Amgen has submitted a supplemental new drug application (sNDA) seeking expanded approval for Otezla in adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
The submission to the US Food and Drug Administration (FDA) is based on data from the Phase III ADVANCE trial.
In this trial, Otezla (apremilast) 30mg twice daily achieved a statistically significant improvement in the primary endpoint of the static Physician's Global Assessment (sPGA) response compared to placebo, at week 16.
In addition, Otezla demonstrated statistically significant improvements in key secondary endpoints compared to placebo.
This includes achieving at least a 75% improvement from baseline in affected body surface area (BSA), change in BSA total score from baseline and change in Psoriasis Area and Severity Index (PASI) total score from baseline at week 16.
Read more: http://www.pharmatimes.com/news/amgen_looks_to_expand_access_to_otezla_in_the_us_1363892

What is the main reason of migraine pain?

Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
In the YOSEMITE and RHINE studies in DME and the TENAYA and LUCERNE studies in nAMD, approximately half of participants eligible for extended dosing with faricimab were able to be treated every four months in the first year.
Results from the four Phase III studies showed that faricimab, when given at intervals of up to four months, offered non-inferior vision gains compared to Regeneron’s Eylea (aflibercept), given every two months.
Read more: http://www.pharmatimes.com/news/roches_vision_loss_therapy_faricimab_extends_time_between_treatments_by_up_to_four_months_1363226

Rentschler Biopharma, a German contract development and manufacturing organisation (CDMO), will build new cell and gene therapy capabilities at a Cell and Gene Therapy (CGT) Catapult site in Stevenage, UK.
As part of the agreement, Rentschler will invest in the site over the next five years to bolster their manufacturing capabilities.
This investment is expected to make a ‘major contribution’ to creating suitable manufacturing capability for cell and gene therapies, the CGT Catapult said in a statement.
The German company will establish manufacturing capability in advanced therapy medicinal products (ATMPs), including adeno-associated virus (AAV) Vectors for clinical trial supply.
Read more: http://www.pharmatimes.com/news/rentschler_biopharma_to_build_cell_and_gene_therapy_manufacturing_capabilities_in_the_uk_1363141

Looking for a research based position in Neuroscience

Collaborative Drug Discovery is introducing it's latest platform for semantic drug data: BioHarmony. We are currently looking for those with experience in the preclinical, clinical, or post-approval fields to beta test this product. To learn more and apply check out: https://www.collaborativedrug.com/cdd-bioharmony-beta-program/

I am in southeastern MA/RI area, and open to a new sales position. I am a tenured professional eager to continue learning and growing in the industry! Thank you for including me in this group!

Open to administrative openings 

In to research smaller biotech companies

Hello,
I am currently a Regulatory Affairs student at Humber College Toronto, Canada. I would love an opportunity to intern at a pharmaceutical or medical device company for summer 2021 or on a long term basis.

Medical Writing for Healthcare Professionals will teach you how to find, get, and most efficiently write work, so you can start your medical writing business today! I created this course specifially to help clinicians and healthcare professionals move from practice writing, whether they aim to do it on the side or transition to a new career.

https://www.udemy.com/course/medical-writing-for-healthcare-professionals/?referralCode=3E385AF692FB2FEBB7F2

Pharmacutical care